LT3498725T - Steroidas su 19-nor c3,3-dipakeistuoju c21-n-pirazolilu, skirtas naudoti terapijoje - Google Patents
Steroidas su 19-nor c3,3-dipakeistuoju c21-n-pirazolilu, skirtas naudoti terapijojeInfo
- Publication number
- LT3498725T LT3498725T LTEP18203320.9T LT18203320T LT3498725T LT 3498725 T LT3498725 T LT 3498725T LT 18203320 T LT18203320 T LT 18203320T LT 3498725 T LT3498725 T LT 3498725T
- Authority
- LT
- Lithuania
- Prior art keywords
- disubstituted
- therapy
- pyrazolyl steroid
- steroid
- pyrazolyl
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013074323 | 2013-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3498725T true LT3498725T (lt) | 2021-09-27 |
Family
ID=51730809
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP18203320.9T LT3498725T (lt) | 2013-04-17 | 2014-04-17 | Steroidas su 19-nor c3,3-dipakeistuoju c21-n-pirazolilu, skirtas naudoti terapijoje |
LTEP14785712.2T LT2986623T (lt) | 2013-04-17 | 2014-04-17 | 19-nor c3,3-dipakeistieji c21-n-pirazolilo steroidai ir jų panaudojimo būdai |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP14785712.2T LT2986623T (lt) | 2013-04-17 | 2014-04-17 | 19-nor c3,3-dipakeistieji c21-n-pirazolilo steroidai ir jų panaudojimo būdai |
Country Status (26)
Country | Link |
---|---|
US (5) | US9512165B2 (lt) |
EP (3) | EP3498725B1 (lt) |
JP (6) | JP6470258B2 (lt) |
KR (4) | KR102239541B1 (lt) |
CN (3) | CN108440633B (lt) |
AU (4) | AU2014256229B2 (lt) |
BR (1) | BR112015026380A8 (lt) |
CA (1) | CA2909545A1 (lt) |
CY (2) | CY1121228T1 (lt) |
DK (2) | DK3498725T3 (lt) |
ES (2) | ES2709434T3 (lt) |
HK (1) | HK1224301A1 (lt) |
HR (2) | HRP20190232T1 (lt) |
HU (2) | HUE055554T2 (lt) |
IL (4) | IL286794B1 (lt) |
LT (2) | LT3498725T (lt) |
MX (2) | MX362543B (lt) |
PL (2) | PL2986623T3 (lt) |
PT (2) | PT3498725T (lt) |
RS (2) | RS58297B1 (lt) |
RU (1) | RU2675855C2 (lt) |
SG (2) | SG10201802389SA (lt) |
SI (2) | SI2986623T1 (lt) |
TR (1) | TR201901745T4 (lt) |
WO (1) | WO2014169833A1 (lt) |
ZA (1) | ZA201507740B (lt) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101405545B1 (ko) | 2005-11-28 | 2014-07-03 | 마리누스 파마슈티컬스 | ganaxolone 제형, 이의 제조방법 및 용도 |
ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
PL2806877T3 (pl) | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス, インコーポレイテッド | 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法 |
DK3021852T3 (da) | 2013-07-19 | 2021-03-15 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
WO2015027227A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
TWI762436B (zh) | 2014-10-16 | 2022-05-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス, インコーポレイテッド | Cns障害を処置するための組成物および方法 |
DK3224269T3 (da) | 2014-11-27 | 2020-05-25 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
CN104558092B (zh) * | 2014-12-29 | 2017-01-18 | 北京理工大学 | 一种甾体皂苷化合物及其制备方法和用途 |
DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
CN104910236B (zh) * | 2015-06-26 | 2016-08-17 | 西北农林科技大学农药研究所 | 吡唑基甾体衍生物及其制备方法、用途 |
CN108135838A (zh) | 2015-10-16 | 2018-06-08 | 马瑞纳斯制药公司 | 包含纳米粒的可注射神经类固醇制剂 |
WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3481844B1 (en) * | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
IL309259A (en) | 2016-07-11 | 2024-02-01 | Sage Therapeutics Inc | C17, C20 and C21 converted neuroactive steroids and methods of using them |
JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. | てんかん性障害の処置のための方法および組成物 |
TWI808945B (zh) * | 2016-08-23 | 2023-07-21 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
CA3075038A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
EP3681510A1 (en) * | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
KR20200096596A (ko) * | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
US20220315621A1 (en) | 2017-12-22 | 2022-10-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP3737687A1 (en) | 2018-01-12 | 2020-11-18 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
WO2019154247A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 甾族类衍生物调节剂、其制备方法和应用 |
EP3750908A4 (en) * | 2018-02-11 | 2022-07-27 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | STEROID DERIVATIVE REGULATORS, PROCESSES FOR THEIR PREPARATION AND THEIR USES |
CN117959309A (zh) * | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
CN111040015B (zh) * | 2018-10-15 | 2022-03-18 | 南京诺瑞特医药科技有限公司 | 19-去甲-c21取代类固醇衍生物 |
CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
BR112021010996A2 (pt) | 2018-12-05 | 2021-08-31 | Sage Therapeutics, Inc. | Esteroides neuroativos e seus métodos de uso |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
AU2020205368A1 (en) * | 2019-01-08 | 2021-08-05 | Chengdu kanghong pharmaceutical co ltd | Steroid compounds, uses and process for preparation therefor |
CA3124703C (en) * | 2019-01-14 | 2023-10-17 | Beijing Xuanyi Pharmasciences Co., Ltd. | Tetrazolone substituted steroids and use thereof |
CN111454318A (zh) | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
CN111770915A (zh) * | 2019-01-31 | 2020-10-13 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
MX2021015942A (es) * | 2019-06-27 | 2022-04-18 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del snc. |
JP2022538301A (ja) | 2019-06-27 | 2022-09-01 | セージ セラピューティクス, インコーポレイテッド | Cns障害を治療するための組成物及び方法 |
BR112021026447A2 (pt) * | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
JP2022543576A (ja) | 2019-08-07 | 2022-10-13 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ステロイド誘導体調節因子の塩及び結晶形態 |
EP4135710A4 (en) * | 2019-09-30 | 2023-12-06 | Eliem Therapeutics (UK) Ltd | COMPOSITIONS FOR PREFERENTIAL POTENTIATION OF SUBTYPES OF GABAA RECEPTORS AND METHODS OF USE THEREOF |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
KR20220134529A (ko) | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
US20230285417A1 (en) * | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
AU2022214187A1 (en) | 2021-01-28 | 2023-07-13 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
JP2024510436A (ja) | 2021-03-17 | 2024-03-07 | セージ セラピューティクス, インコーポレイテッド | 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド |
BR112023022264A2 (pt) | 2021-04-29 | 2024-01-23 | Sage Therapeutics Inc | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo |
JP2024515830A (ja) | 2021-04-29 | 2024-04-10 | セージ セラピューティクス, インコーポレイテッド | 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド |
WO2023158668A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
NL297205A (lt) * | 1962-08-28 | |||
US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
US3511860A (en) * | 1966-09-26 | 1970-05-12 | Syntex Corp | Synthesis of 19-nor and ring a aromatic steroids and intermediates therefor |
NL6801449A (lt) * | 1968-02-01 | 1969-08-05 | ||
BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
DK134348C (da) | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
AU2657292A (en) | 1991-09-13 | 1993-04-27 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
JP4008024B2 (ja) * | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Gabaaレセプター複合体と相互作用させるための化合物 |
CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
AU691905B2 (en) | 1994-02-14 | 1998-05-28 | Purdue Pharma Ltd. | Androstanes and pregnanes for allosteric modulation of GABA receptor |
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
US5792757A (en) * | 1994-08-04 | 1998-08-11 | Pherin Pharmaceuticals | 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function |
PT808325E (pt) | 1994-11-23 | 2001-06-29 | Cocensys Inc | Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba |
PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
YU77701A (sh) * | 1999-04-29 | 2005-07-19 | Euro-Celtique S.A. | 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
ATE297406T1 (de) | 2000-02-18 | 2005-06-15 | Taiho Pharmaceutical Co Ltd | Verfahren zur herstellung von steroid-derivaten |
US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
EP1330467B1 (en) | 2000-11-03 | 2007-05-02 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
EP1608671B1 (en) | 2003-03-24 | 2010-01-06 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
US20070099880A1 (en) | 2003-11-24 | 2007-05-03 | Blizzard Timothy A | Estrogen receptor modulators |
US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
KR20070050987A (ko) * | 2004-09-03 | 2007-05-16 | 셀진 코포레이션 | 치환된 헤테로시클릭 화합물 및 그의 용도 |
WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
EP2263675A3 (en) | 2005-06-09 | 2011-05-18 | Euro-Celtique S.A. | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
KR20090006148A (ko) * | 2006-04-05 | 2009-01-14 | 와이어쓰 | 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체 |
CN101506221B (zh) * | 2006-09-19 | 2012-09-12 | 索尔瓦药物有限公司 | 雌三烯衍生物及其作为17β-羟基类固醇脱氢酶抑制剂的用途 |
US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
JP5663303B2 (ja) | 2007-06-15 | 2015-02-04 | リサーチ トライアングル インスティテュート | Gabaレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド |
GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
KR100958286B1 (ko) * | 2007-11-15 | 2010-05-19 | 한국과학기술원 | a1G T―타입 칼슘 채널을 억제하여 본태성 진전증을예방 및 치료하는 방법 |
US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
CZ301216B6 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
WO2012013816A1 (en) | 2010-07-30 | 2012-02-02 | Medexis S.A. | Compounds and methods for treating neoplasia |
EP2667876A2 (en) | 2010-12-15 | 2013-12-04 | Harbor BioSciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
ES2762098T3 (es) | 2011-03-23 | 2020-05-22 | Etsuro Ito | Método y kit para medición de superalta sensibilidad de proteína y ácido nucleico, y nuevo sustrato enzimático |
EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
PT2753632T (pt) * | 2011-09-08 | 2023-08-17 | Sage Therapeutics Inc | Esteróides neuroactivos, composições e respectivas utilizações |
ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3336097B1 (en) | 2012-06-19 | 2020-08-19 | Intercept Pharmaceuticals, Inc. | Preparation of the non-crystalline form of obeticholic acid |
WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティWashington University | 向神経活性19−アルコキシ−17−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス, インコーポレイテッド | 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法 |
DK3021852T3 (da) | 2013-07-19 | 2021-03-15 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
WO2015027227A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
PL3149018T3 (pl) | 2014-05-29 | 2021-01-25 | Sage Therapeutics, Inc. | Sterydy neuroaktywne, kompozycje i ich zastosowania |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10172870B2 (en) | 2014-09-02 | 2019-01-08 | The Texas A&M University System | Method of treating organophosphate intoxication by administration of neurosteroids |
TWI762436B (zh) | 2014-10-16 | 2022-05-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス, インコーポレイテッド | Cns障害を処置するための組成物および方法 |
DK3224269T3 (da) | 2014-11-27 | 2020-05-25 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス, インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
CN108135838A (zh) | 2015-10-16 | 2018-06-08 | 马瑞纳斯制药公司 | 包含纳米粒的可注射神经类固醇制剂 |
US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
IL309259A (en) | 2016-07-11 | 2024-02-01 | Sage Therapeutics Inc | C17, C20 and C21 converted neuroactive steroids and methods of using them |
EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
TWI808945B (zh) | 2016-08-23 | 2023-07-21 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
MX2020001732A (es) | 2017-08-31 | 2020-03-20 | Takeda Pharmaceuticals Co | Tratamiento de las afecciones del sistema nervioso central. |
CA3075038A1 (en) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
CA3079259A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
JP2021523938A (ja) | 2018-05-04 | 2021-09-09 | アセラス ファーマシュウティカルズ コーポレーション | 神経ステロイド誘導体およびその使用 |
-
2014
- 2014-04-17 JP JP2016507995A patent/JP6470258B2/ja active Active
- 2014-04-17 LT LTEP18203320.9T patent/LT3498725T/lt unknown
- 2014-04-17 HU HUE18203320A patent/HUE055554T2/hu unknown
- 2014-04-17 PL PL14785712T patent/PL2986623T3/pl unknown
- 2014-04-17 TR TR2019/01745T patent/TR201901745T4/tr unknown
- 2014-04-17 SI SI201431072T patent/SI2986623T1/sl unknown
- 2014-04-17 HU HUE14785712A patent/HUE041369T2/hu unknown
- 2014-04-17 SI SI201431867T patent/SI3498725T1/sl unknown
- 2014-04-17 EP EP18203320.9A patent/EP3498725B1/en active Active
- 2014-04-17 DK DK18203320.9T patent/DK3498725T3/da active
- 2014-04-17 AU AU2014256229A patent/AU2014256229B2/en active Active
- 2014-04-17 MX MX2015014600A patent/MX362543B/es active IP Right Grant
- 2014-04-17 KR KR1020157032454A patent/KR102239541B1/ko active IP Right Grant
- 2014-04-17 PT PT182033209T patent/PT3498725T/pt unknown
- 2014-04-17 KR KR1020217010184A patent/KR102396328B1/ko active IP Right Grant
- 2014-04-17 LT LTEP14785712.2T patent/LT2986623T/lt unknown
- 2014-04-17 CN CN201810263557.2A patent/CN108440633B/zh active Active
- 2014-04-17 DK DK14785712.2T patent/DK2986623T3/en active
- 2014-04-17 SG SG10201802389SA patent/SG10201802389SA/en unknown
- 2014-04-17 WO PCT/CN2014/075594 patent/WO2014169833A1/en active Application Filing
- 2014-04-17 EP EP14785712.2A patent/EP2986623B1/en active Active
- 2014-04-17 RU RU2015149008A patent/RU2675855C2/ru active
- 2014-04-17 CN CN202110717941.7A patent/CN113527400A/zh active Pending
- 2014-04-17 IL IL286794A patent/IL286794B1/en unknown
- 2014-04-17 ES ES14785712T patent/ES2709434T3/es active Active
- 2014-04-17 US US14/785,171 patent/US9512165B2/en active Active
- 2014-04-17 IL IL310348A patent/IL310348A/en unknown
- 2014-04-17 EP EP21178047.3A patent/EP3909966A1/en active Pending
- 2014-04-17 KR KR1020227015252A patent/KR102614507B1/ko active IP Right Grant
- 2014-04-17 SG SG11201508550XA patent/SG11201508550XA/en unknown
- 2014-04-17 CA CA2909545A patent/CA2909545A1/en active Pending
- 2014-04-17 KR KR1020237042912A patent/KR20230172622A/ko active Application Filing
- 2014-04-17 RS RS20190136A patent/RS58297B1/sr unknown
- 2014-04-17 BR BR112015026380A patent/BR112015026380A8/pt not_active Application Discontinuation
- 2014-04-17 PL PL18203320T patent/PL3498725T3/pl unknown
- 2014-04-17 RS RS20211106A patent/RS62312B1/sr unknown
- 2014-04-17 ES ES18203320T patent/ES2886182T3/es active Active
- 2014-04-17 PT PT14785712T patent/PT2986623T/pt unknown
- 2014-04-17 CN CN201480031476.XA patent/CN105339381B/zh active Active
-
2015
- 2015-10-15 IL IL242089A patent/IL242089B/en active IP Right Grant
- 2015-10-15 ZA ZA2015/07740A patent/ZA201507740B/en unknown
- 2015-10-16 MX MX2022007490A patent/MX2022007490A/es unknown
-
2016
- 2016-08-01 HK HK16109159.0A patent/HK1224301A1/zh unknown
- 2016-10-19 US US15/297,845 patent/US10172871B2/en active Active
-
2018
- 2018-06-27 US US16/020,641 patent/US10342810B2/en active Active
- 2018-09-04 JP JP2018164995A patent/JP6784735B2/ja active Active
- 2018-09-04 JP JP2018164996A patent/JP6710730B2/ja active Active
- 2018-12-11 AU AU2018278844A patent/AU2018278844B2/en active Active
-
2019
- 2019-02-05 CY CY20191100154T patent/CY1121228T1/el unknown
- 2019-02-05 HR HRP20190232TT patent/HRP20190232T1/hr unknown
- 2019-05-31 US US16/428,386 patent/US11241446B2/en active Active
-
2020
- 2020-09-28 JP JP2020161921A patent/JP7085601B2/ja active Active
- 2020-10-15 AU AU2020256400A patent/AU2020256400B2/en active Active
- 2020-11-04 IL IL278487A patent/IL278487B/en unknown
-
2021
- 2021-08-13 HR HRP20211314TT patent/HRP20211314T1/hr unknown
- 2021-09-07 CY CY20211100787T patent/CY1125416T1/el unknown
- 2021-12-23 US US17/560,732 patent/US20220110950A1/en active Pending
-
2022
- 2022-01-26 JP JP2022010037A patent/JP2022058758A/ja active Pending
- 2022-07-12 AU AU2022205157A patent/AU2022205157A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129979A patent/JP2023154010A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286794A (en) | 19- nor c3, 3- dimethomer c21- n- pyrazole Steroids and methods of using them | |
HK1221908A1 (zh) | 多特異 試劑,其製備方法和用途 | |
IL245467B (en) | A receptor for t cells that has been modified or a part of it that binds to an antigen, a medical agent containing it and their uses | |
ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
EP3060159A4 (en) | Intra-oral light-therapy apparatuses and methods for their use | |
DK2986624T3 (da) | Neuroaktive 19-nor-steroider til terapeutisk anvendelse | |
IL244427A0 (en) | Systems, installations and methods in treatment with anti- tl1a | |
GB2528395B (en) | Apparatus and methods for geosteering | |
IL245445A0 (en) | Devices, kits and methods for osmotic administration of drugs | |
EP2945643A4 (en) | Therapeutic agents, compositions, and methods for glycemic control | |
EP3087736A4 (en) | Measuring apparatus, system, and program | |
EP3065712A4 (en) | Microparticles, methods for their preparation and use | |
EP2984543A4 (en) | TOUCH PANEL, PREPARATION METHOD THEREFOR, AG-PD-ND ALLOY FOR TOUCH SCREEN | |
IL241768B (en) | 2beta, 3alpha, 5alpha-trihydroxy-androstane-6-one, methods for its preparation and uses | |
EP3029589A4 (en) | Device for permitting program, program transaction device and method for permitting program thereof | |
EP3010178A4 (en) | Calculation device, calculation method, and program | |
IL243790B (en) | Devices, kits and methods of connection | |
HK1204001A1 (en) | Rna fragment, preparation method therefor, and use thereof rna | |
AU2013903187A0 (en) | Chair for reinforcement | |
AU2013903781A0 (en) | Support for use in mine | |
GB201302884D0 (en) | Novel methods for diagnosis and therapy |